Recruiting

Testing AI to detect early dry eye disease from eye images

Plain-English translation of NCT07446582 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

What is this trial?

This trial is testing whether an artificial intelligence tool called DeepMSI can detect early signs of age-related macular degeneration (a condition affecting central vision) just as well as experienced eye doctors can. The study will take special multispectral images of participants' eyes and compare how the AI and eye specialists each interpret those images to see if they're equally accurate.

Early detection of macular degeneration is crucial for preserving vision, but it requires expert eye doctors to review images carefully. This research aims to find out whether AI technology could help identify this disease reliably, potentially making screening faster and more accessible to more people.

Do you qualify?

You likely qualify if…

you are over 40 years old
you have been diagnosed with dry age-related macular degeneration (AMD) with drusen or geographic atrophy, or you have healthy eyes with no AMD diagnosis
you have had at least one prior eye clinic visit with imaging records available
you can understand and are willing to sign an informed consent form
you can maintain steady eye focus during the imaging procedure

You likely don't qualify if…

you have cataracts, corneal clouding, or other eye surface problems that would prevent clear imaging
you have had eye surgery within the past 3 months (except injections for AMD treatment)
you have other eye conditions like diabetic retinopathy, retinal vein or artery blockage, or history of retinal detachment
you have severe dry eye disease or unstable eye conditions like active infections or recent trauma
you have head tremors, nystagmus (involuntary eye movements), or other conditions that prevent steady eye fixation during imaging

What participation looks like

You will visit a clinic where your eyes will be scanned using a special imaging device called the MSI-120 that takes multispectral pictures of your retina. The images will then be analyzed by both artificial intelligence software and experienced eye doctors independently, and researchers will compare their results. The study involves about 1,000 participants and is observational, meaning you're not taking any medication — just having your eyes scanned and assessed.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(1 site)

United States

Contact Lens & Vision, Woodbridge, New Jersey